PitchSend

Nuvectis Pharma Investor Presentation Deck

Targeting YES1 in Cancers of Squamous Cell Origin Single Agent Development Strategy YES1/SRC "off" SH3 SH2 P PYS30 SE33 NXXP500 1419 Kinase V830 SH2 YES1/SRC "on" Chels 132 P DV419 Kinase Created with BioRender.com NuvectisPharma, Inc. P- Tyr Rassf YAP/TAZ P. Tyr YAP/TAZ TEAD xoxoa P P FRMD6 KIBRA MST1/2 SAV1 LATS1/2 MOB1 FAT 1-4 14-3-3 P YAP/TAZ Merlin P P- Ser -(50) Degradation Targets involved in organ size, stem cell renewal, replication, and survival: • ID1 • MYC .FGF1 • CTGF • Cyclin D . AREG • SMAD High Nuclear YAP Cells Per Well (%) 30 Low Nuclear YAP 5.0 High Nuclear YAP NXP900 - IC50 for YAP1 nuclear localization: 24.3nM log(Concentration [UM]) 0.0 Genetic alterations in the hippo pathway (FAT1-4, YAP1, TAZ) are highly prevalent in cancers of squamous cell origin and confer sensitivity to NXP900 ➜ patient selection YES1 drives tumor growth via activating phosphorylation and nuclear localization of YAP1 →Target is central to disease etiology Significant unmet medical need opportunities within the squamous cancer universe Regulatory opportunity 17

View entire presentation